期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Effect of cDNA fragments in different length derived from Potato Virus Y coat protein gene on the induction of RNA-mediated virus resistance 被引量:5
1
作者 ZHU Junhua ZHU Xiaoping +3 位作者 WEN Fujiang BAI Qingrong ZHU Changxiang SONG Yunzhi 《Science China(Life Sciences)》 SCIE CAS 2004年第4期382-388,共7页
We have reported that cDNA derived from entire coat protein (CP) gene of potato virus Y (PVY) could induce resistance to PVY infection in transgenic tobacco plants, and the resistance was further demonstrated to be RN... We have reported that cDNA derived from entire coat protein (CP) gene of potato virus Y (PVY) could induce resistance to PVY infection in transgenic tobacco plants, and the resistance was further demonstrated to be RNA-mediated rather than coat protein-mediated. In this study, we cloned cDNA fragments of 202 bp, 417 bp, and 603 bp in length derived from the 3′ end of the PVY CP gene, and the cDNA fragments were introduced into tobacco (var. NC89) plants via Agrobacterium-mediated transformation system. The results of resistance assay showed that the CP cDNA fragments of 417 bp and 603 bp could confer resistance of the trans-genic plants to PVY infection, but the fragment of 202 bp in length could not. Molecular analysis revealed that the resistance was RNA-mediated, which is believed to be a result of post-transcriptional gene silencing. The results indicate that the length of cDNA fragments needed for resistance induction was located somewhere between 202 bp and 417 bp from the 3′ end of PVY CP gene. 展开更多
关键词 PVY partial length of cp gene fragments transgenic tobacco plants RNA-mediated resistance post-transcrip-tional gene silencing.
原文传递
左乙拉西坦添加治疗难治性部分性癫的疗效及其与多药耐药基因的相关性研究:随机双盲安慰剂对照临床试验 被引量:8
2
作者 郑兴珍 武士京 +1 位作者 夏敏 李倩 《中国现代神经疾病杂志》 CAS 2009年第2期173-177,共5页
目的探讨左乙拉西坦添加治疗难治性部分性癫的临床疗效及其与多药耐药基因1(MDR1)的相关性。方法30例诊断明确的难治性部分性癫患者按照随机双盲安慰剂对照研究方法,分别予抗癫药物左乙拉西坦添加治疗和安慰剂治疗,初始剂量1g(2次/d... 目的探讨左乙拉西坦添加治疗难治性部分性癫的临床疗效及其与多药耐药基因1(MDR1)的相关性。方法30例诊断明确的难治性部分性癫患者按照随机双盲安慰剂对照研究方法,分别予抗癫药物左乙拉西坦添加治疗和安慰剂治疗,初始剂量1g(2次/d),2周后增至2g(2次/d),再2周后增至3g(2次/d),维持治疗12周后逐渐减量,进入减量/开放期。评价患者治疗期(16周)每周癫发作频率与回顾性基线期比较降低的百分比及发作频率减少50%的有效率。聚合酶链反应-限制性片段长度多态性检测患者基因型。结果30例患者中27例完成临床试验。基因型检测共检出CC基因型16例,左乙拉西坦添加治疗组(治疗组)9例(完全控制1例、显效3例、有效2例,发作频率减少50%的有效率为66.67%),安慰剂组7例(仅1例有效,发作频率减少50%的有效率为14.29%),组间比较差异具有统计学意义(Z=蛳2.013,P=0.042);CT+TT基因型11例,治疗组9例(完全控制1例、显效2例、有效4例,发作频率减少50%的有效率为77.78%),安慰剂组2例。治疗组CC基因型与CT+TT基因型患者疗效比较,差异无统计学意义(Z=-0.193,P=0.888)。结论左乙拉西坦作为难治性部分性癫患者的添加治疗药物临床效果良好,其主要药理学机制可能与左乙拉西坦是非多药耐药基因1编码的P-糖蛋白底物有关。 展开更多
关键词 部分性 吡拉西坦 基因 MDR P糖蛋白类 多态性 限制性片段长度
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部